Forma Therapeutics to discover candidates for Singapore centre
This article was originally published in Scrip
Forma Therapeutics is to apply its proprietary technology to discover new compounds for Singapore's Experimental Therapeutics Centre. The financial terms of the agreement were not disclosed.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.